MPG.eBooks - Staff View: PCSK-9 inhibitors for hyperlipidemia

Read Now

Alirocumab and evolocumab are expensive drugs (annual cost per patient > Can

Bibliographic Details
Main Authors:	Banerjee, Srabani, Wells, Charlotte (Author), Grobelna, Aleksandra (Author)
Corporate Author:	Canadian Agency for Drugs and Technologies in Health
Format:	eBook
Language:	English
Published:	Ottawa CADTH 2017, June 6, 2017
Series:	CADTH rapid response report: summary with critical appraisal
Online Access:	https://www.ncbi.nlm.nih.gov/books/NBK524911
Collection:	National Center for Biotechnology Information - Collection details see MPG.ReNa


LEADER	01101nam a2200253 u 4500
001	EB002010719
003	EBX01000000000000001173618
005	00000000000000.0
007	tu\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|\|
008	220201 r \|\|\| eng
100	1		\|a Banerjee, Srabani
245	0	0	\|a PCSK-9 inhibitors for hyperlipidemia \|h Elektronische Ressource \|b a review of the comparative clinical effectiveness \|c Srabani Banerjee, Charlotte Wells, Aleksandra Grobelna
260			\|a Ottawa \|b CADTH \|c 2017, June 6, 2017
300			\|a 1 PDF file (21 pages) \|b illustrations
505	0		\|a Includes bibliographical references
700	1		\|a Wells, Charlotte \|e [author]
700	1		\|a Grobelna, Aleksandra \|e [author]
710	2		\|a Canadian Agency for Drugs and Technologies in Health
041	0	7	\|a eng \|2 ISO 639-2
989			\|b NCBI \|a National Center for Biotechnology Information
490	0		\|a CADTH rapid response report: summary with critical appraisal
856	4	0	\|u https://www.ncbi.nlm.nih.gov/books/NBK524911 \|3 Volltext
082	0		\|a 610
520			\|a Alirocumab and evolocumab are expensive drugs (annual cost per patient > Can